We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Nurix Therapeutics Inc | NASDAQ:NRIX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.41 | -2.94% | 13.54 | 13.00 | 13.54 | 14.15 | 13.23 | 14.05 | 335,009 | 22:45:22 |
From May 2023 to May 2024
By Stephen Nakrosis
Nurix Therapeutics on Wednesday said the Food and Drug Administration placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies.
Nurix said NX-2127 is currently being evaluated in patients with relapsed or refractory B cell malignancies.
The biopharmaceutical company said the hold comes after it informed the FDA it intends transition to an improved manufacturing process. None of the company's other drug programs are affected by the NX-2127 manufacturing process improvement, it said.
Screening and enrollment of new study participants has been paused, but patients currently enrolled may continue to receive treatment in accordance with the ongoing study protocol, Nurix said. The company also said it is working with the FDA to resolve the partial clinical hold as soon as possible.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 01, 2023 17:01 ET (21:01 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Nurix Therapeutics Chart |
1 Month Nurix Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
